Riskpilot← Back to searchSign inGet full accessOncopeptides Innovation 1 AB
ABActiveOrg 5593798803Luntmakargatan 46Research and experimental development on natural sciences and engineering · NACE 7210Est. 20220 employees
Revenue 2024
SEK -1
EBITDA margin
1454083600.0%
-107% vs 2023
Equity ratio
0.1%
Financial strength
Net profit 2024
SEK 0
-100% vs 2023
| Revenue | SEK -1 | — |
| EBITDA | SEK -14,5M | -107% |
| Net profit | SEK 0 | -100% |
| Total assets | SEK 27,5M | +194% |
| Equity | SEK 31K | +0% |
| Employees | 0 | — |
Legal name
Oncopeptides Innovation 1 AB
Org number
5593798803
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
10 maj 2022
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget har till föremål för sin verksamhet att, direkt eller indirekt, utöva forskning inom läkemedelsindustrin, hantera immateriella tillgångar, och därmed förenlig verksamhet.
Address
Luntmakargatan 46
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | −0 |
| Staff expenses | — | −0 | — | — |
| EBITDA | −693 | −693 | −7 016 | −14 541 |
| Depreciation & amort. | −0 | −0 | — | — |
| EBIT | −693 | −693 | −7 016 | −14 541 |
| Net financials | — | 0 | 41 | 119 |
| Profit before tax | 7 | 7 | 1 | 0 |
| Tax | −1 | 1 | — | — |
| Net profit | 6 | 6 | 1 | 0 |
| Item | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 593 | 593 | 9 363 | 27 535 |
| Equity | 31 | 31 | 31 | 31 |
| Long-term debt | 0 | 0 | — | — |
| Short-term debt | 563 | 563 | 9 331 | 27 504 |
| Total debt | 563 | 563 | 9 331 | 27 504 |
EBITDA margin
-1454083600.0%
This company
15.8%
Market median
-9203060859% vs market
20222024
Equity ratio
0.1%
This company
38.2%
Market median
-100% vs market
20222024
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20222024
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20222024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
874.10×
This company
0.62×
Market median
-140884% vs market
20222024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-05-10 – 2022-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-05-01 – 2022-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
AK Chief Auditor | Chief Auditor | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Former (14) | ||
| Deputy Board Member | 2022 – 2022 | |
| Board of Directors | 2023 – 2023 | |
| Deputy Board Member | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
| Chairman | 2023 – 2023 | |
| Board of Directors | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
| Deputy Board Member | 2022 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Oncopeptides AB
Oncopeptides Innovation 1 AB Board members of Oncopeptides Innovation 1 AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Kristina Svanberg | Chief Auditor | 0 companies |
| Hans Jarl Rutger Arnhult | Deputy Board Member | 0 companies |
| Karl Daniel Barck | Board of Directors | 0 companies |
| Bo Daniel Falk | Deputy Board Member | 0 companies |
| Viktor Elias Bergman Gullmark | Deputy Board Member | 0 companies |
| Emma Maria Birgitta Wik | Deputy Board Member | 0 companies |
| Marie Charlotte Svensson | Board of Directors | 0 companies |
| Andreas Hans Eddie Ottosson | Deputy Board Member | 0 companies |
| Anna Matilda Sjödin | Deputy Board Member | 0 companies |
| Eric Henrik Bergentoft | Chairman | 0 companies |
| Holger Lembrér | Chairman | 0 companies |
| Lars Anders Larsson | Board of Directors | 0 companies |
| Anna Carolina Maria Bjarnhagen | Deputy Board Member | 0 companies |
| Eva Sabina Marianne Nordström | Board of Directors | 0 companies |
| Rolf Stefan Janse | Deputy Board Member | 0 companies |
| Eva Evelina Evelyn Sjöstedt | Deputy Board Member | 0 companies |
| Mari Sinikka Kovaniemi Feldt | Deputy Board Member | 0 companies |
| Olina Kristina Maria Wåhlstedt | Deputy Board Member | 0 companies |